Jangada Mines (LON: JAN) says it has exceptional high-grade gold results from sampling across multiple targets at the Molly gold project in Brazil. These exceed expectations. There is also silver, copper, lead and zinc. The characteristics are similar to producing mines in the region. There are seven highly prospective target areas. The share price gained 11.5% to 0.725p.
Shares in Pacso (LON: PACS), formerly Agriterra, returned from suspension after publishing accounts for the year to March 2026. The agricultural activities in Mozambique have been sold with final regulatory approval in August when the company became a shell. The share price recovered 11.1% to 0.35p.
Floorcoverings distributor Likewise (LON: LIKE) growth in revenues accelerated in October and its is 22.8% for the year to date. This led to an upgrade in full year forecast pre-tax profit from £5m to £6m. The purchases from Headlam are being integrated and should enhance earnings next year and the pre-tax forecast has been upgraded from £6.4m to £8m. The share price is 7.14% ahead at 45p, which is approaching the all time high.
There was a strong full year performance from contract and permanent recruitment company Gattaca (LON: GATC) with all of its divisions showing growth. The fastest growth was in the defence sector. In recent years the growth has come from the contract operations, but there are signs of improvement in permanent recruitment. Net fee income was 11% ahead at £41.5m with a contribution from cybersecurity-focused InfoSec. Cost savings and efficiencies helped underlying pre-tax profit jump from £3.3m to £6.1m. Net cash was £17.3m at the end of July 2026. The full year dividend is doubled at 6p/share. The share price improved 7.11% to 135.5p.
Audio equipment manufacturer Focusrite (LON: TUNE) increased revenues by 3% to £90.3m and pre-tax profit improved from £8m to £9.8m. The balance sheet remains strong with net debt down to £1.5m. The content creation division revenues grew event though there was distributor destocking in the US after they were built up in the previous year – end sales to customers grew. A weak China market was partly responsible for a dip in audio reproduction revenues. Full year pre-tax profit could improve from £12.5m to £14.2m. The share price increased 6.16% to 232.5p.
FALLERS
Allergy Therapeutics (LON: AGY) says challenging market conditions and lack of liquidity make it difficult to raise money and therefore it has decided to ask shareholders to agree to the biotech company leaving AIM. Two investors own 89% of the company. Allergy Therapeutics is still considering a listing in Hong Kong. The share price slumped 60.7% to 1.375p.
Iron replacement treatment supplier Shield Therapeutics (LON: STX) reported third quarter revenues of $11.5m, which is slightly lower than in the second quarter, although US sales of ACCRUFeR were 5% ahead. The selling price is recovering with prescription volumes flat. The cost of taking full commercial control in the US means that there will be a loss this year. The share price dived 34.6% to 3.6p.
Ukrainian dairy products producer Ukrproduct (LON: UKR) says since the publication of interims the security environment in Ukraine has got worse with interruptions to energy supply. The company’s facilities have been hit by missiles. The company is operating under operational and financial constraints. A subsidiary is acquiring EBRD’s rights and interests in the facility provided to the group for €335,000 in cash. The deal has still to be completed and the board is assessing the accounting implications. There is likely to be an accounting gain, but this does not relate to a cash inflow. The share price declined 22.6% to 6p.
Zanaga Iron Ore Company (LON: ZIOC) has completed bulk sampling at the Zanaga project. The sample will undergo pilot testing. Financing is still at the letter of intent stage. The first $5m payment from RAM is due by the end of the month and this would fund the next phase. The share price fell 4.46% to 2.895p.